Polycythemia Cell Models for Research

Polycythemia is a hematologic disorder characterized by increased red blood cell mass, classified as primary (polycythemia vera, PV) or secondary. According to WHO 2022 classification, PV is a myeloproliferative neoplasm with an annual incidence of approximately 0.4 to 2.8 per 100,000 individuals globally. The median age at diagnosis is 60 years, with a slight male predominance. Key risk factors include age, male sex, and somatic mutations in JAK2, CALR, or MPL. Thromboembolic events are a major cause of morbidity, occurring in 12-39% of patients. According to NCI SEER data (2015-2019), the 5-year relative survival for PV is approximately 90%, but survival decreases with age and in those progressing to myelofibrosis or acute myeloid leukemia (AML). Secondary polycythemia, often due to chronic hypoxia or erythropoietin-secreting tumors, has a prevalence of 1-2% in adults, with outcomes dependent on the underlying cause.

Polycythemia serves as an excellent model for studying myeloproliferative neoplasms, cytokine signaling, and clonal hematopoiesis. The discovery of JAK2 V617F in 2005 revolutionized understanding of PV pathogenesis, and subsequent findings of CALR and MPL mutations highlighted the role of cytokine receptor signaling. Public datasets such as TCGA, COSMIC, and ClinVar provide extensive genomic data. Open questions include the mechanisms of progression to myelofibrosis/AML, the role of non-driver mutations, and the development of targeted therapies beyond JAK inhibitors. The disease offers a unique opportunity to study the interplay between genetic mutations and the bone marrow microenvironment.

The pathogenesis of polycythemia involves constitutive activation of cytokine signaling pathways, primarily due to mutations in JAK2, CALR, or MPL. Key pathways include:

1. JAK-STAT pathway: Mutant JAK2 V617F or MPL activates STAT3/5, driving proliferation and survival.

2. PI3K/AKT/mTOR pathway: Activated downstream of JAK2, promoting cell growth and metabolism.

3. MAPK/ERK pathway: Contributes to proliferation and differentiation blockade.

4. Epigenetic regulation: Mutations in TET2, ASXL1, and IDH1/2 alter DNA methylation and chromatin structure, contributing to clonal evolution.

These pathways are attractive targets for therapeutic intervention, and gene-edited cell models can help dissect their specific contributions.

Data from TCGA, COSMIC, and ClinVar.

The signaling networks in polycythemia are characterized by constitutive activation and crosstalk:

• • JAK-STAT network:
• • JAK2 V617F phosphorylates STAT3/5, leading to nuclear translocation and target gene transcription (e.g., PIM1, BCL-XL).
• • Negative regulators such as SOCS proteins are often downregulated.
• • PI3K/AKT/mTOR network:
• • Activated by JAK2 via adaptor proteins, promoting cell cycle progression and survival.
• • mTOR inhibitors show preclinical efficacy but limited clinical benefit.
• • MAPK/ERK network:
• • Activated in a subset of patients, contributing to proliferation.
• • Epigenetic modifiers:
• • TET2 and ASXL1 mutations disrupt normal hematopoiesis and promote clonal dominance.

These networks are interconnected, and gene-edited models can help identify nodes for combination therapy.

Organoids derived from patient bone marrow or peripheral blood mononuclear cells can recapitulate the disease phenotype and are valuable for drug testing. They offer advantages such as patient-specific genetics and the ability to study clonal evolution.

Animal models are crucial for understanding disease progression and testing therapies:

• • Genetically engineered mouse models (GEMMs):
• • JAK2 V617F knock-in mice develop PV-like disease with polycythemia, splenomegaly, and bone marrow fibrosis.
• • MPL W515L retroviral transduction models produce a myeloproliferative phenotype.
• • Patient-derived xenografts (PDX):
• • Immunodeficient mice engrafted with patient cells allow study of human disease in vivo.
• • Induced models:
• • Hydroxyurea or erythropoietin administration can induce secondary polycythemia.

These models have limitations, including species differences and incomplete recapitulation of human disease.

CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and point mutations. For polycythemia, key models include:

• • JAK2 V617F knock-in in hematopoietic cell lines (e.g., Ba/F3, HEL) to study constitutive signaling and drug response.
• • CALR knockout or mutant knock-in to investigate its role in MPL activation.
• • MPL W515L knock-in to model essential thrombocythemia and primary myelofibrosis.
• • TET2 knockout to study epigenetic dysregulation and clonal evolution.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible and validated tools. These models are essential for target validation, drug screening, and mechanistic studies. They allow researchers to compare isogenic pairs (wild-type vs. mutant) to dissect the specific effects of mutations.

Gene-edited cell lines enable functional validation of genetic alterations identified in polycythemia. For example:

• • Knockout of JAK2 V617F in HEL cells reduces STAT5 phosphorylation and cell proliferation, confirming its driver role.
• • Knock-in of CALR mutations in UT-7 cells activates MPL signaling, demonstrating the mutant's oncogenic potential.
• • CRISPR screens can identify synthetic lethal interactions, such as dependencies on specific kinases or epigenetic regulators.

These studies provide insights into disease mechanisms and potential therapeutic targets.

Isogenic pairs of cell lines (wild-type vs. mutant) are powerful tools for drug discovery:

• • High-throughput screening of small molecule libraries to identify compounds that selectively inhibit mutant cells.
• • Modeling resistance to JAK inhibitors (e.g., ruxolitinib) by generating resistant clones through chronic exposure and CRISPR mutagenesis.
• • Testing combination therapies targeting JAK-STAT and PI3K/AKT pathways.

Such screens can reveal novel drug candidates and resistance mechanisms, guiding clinical trial design.

CRISPR-based synthetic lethality screens in gene-edited cells can uncover biomarkers predictive of drug response. For example:

• • Genome-wide knockout screens in JAK2 V617F cells treated with JAK inhibitors identify genes whose loss sensitizes or confers resistance.
• • Epigenetic screens can reveal dependencies on chromatin modifiers, suggesting combination therapies.
• • These findings can be translated into predictive biomarkers for patient stratification.

Gene-edited models thus bridge the gap between genomics and clinical application.